UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 26, 2013
Bacterin International Holdings, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
| ||
| Delaware | ||
|
(State or Other Jurisdiction of Incorporation)
| ||
| 001-34951 | 20-5313323 | |
| (Commission File Number) |
(IRS Employer Identification No.)
| |
|
600 Cruiser Lane Belgrade, Montana |
59714 | |
| (Address of Principal Executive Offices) |
(Zip Code)
| |
| (406) 388-0480 | ||
|
(Registrant’s Telephone Number, Including Area Code)
| ||
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||
Item 7.01 Regulation FD Disclosure.
The Company has issued a press release entitled “Bacterin to Present at the LD Micro Conference” which is attached as Exhibit 99.1 and incorporated herein.
The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No | Description | |
|
99.1 |
Press Release of Bacterin International Holdings, Inc. dated November 26, 2013 entitled “Bacterin to Present at the LD Micro Conference” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 26, 2013 | BACTERIN INTERNATIONAL HOLDINGS, INC. |
By: /s/ Daniel Goldberger_______________________
Name: Daniel Goldberger
Title: CEO
EXHIBIT INDEX
|
99.1 |
Press Release of Bacterin International Holdings, Inc. dated November 26, 2013 entitled “Bacterin to Present at the LD Micro Conference” |
Exhibit 99.1
Bacterin to Present at the LD Micro Conference
BELGRADE, MT, November 26, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger, and CFO, John Gandolfo, will present at the LD Micro Conference, to be held December 3-5, 2013 at the Luxe Sunset Bel Air in Los Angeles. Bacterin's presentation will take place Thursday, December 5, 2013 at 1:30 PM PST.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Info" section of the Company's website at www.bacterin.com. A replay of the conference presentation will also be available.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Contact:
COCKRELL GROUP
877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com